Bridion Injection, Solution
Product Images NDC 71872-7187

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Bridion (NDC 71872-7187). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medical Purchasing Solutions, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71872-7187-1.pdp (71872 7187 1)

Label for Bridion (sugammadex) Injection 200 mg/2 mL (100 mg/mL) single-dose vial. The label states intravenous use only, storage instructions, and manufacturing details including Medical Purchasing Solutions as the repackager and distributor, and original manufacturing by N.V Organon in the Netherlands and Merck Sharp & Dohme Corp. in the USA.*

FDA Label Image

Chemical Structure (Bridion 01)

Chemical structure of sugammadex, the active ingredient in BRIDION injection solution 100 mg/mL, showing the detailed molecular arrangement of atoms and bonds in a complex cyclic structure.*

FDA Label Image

Chemical Structure (Bridion 02)

Chemical structure diagram of sugammadex, the active ingredient in BRIDION. The diagram shows the molecular arrangement including multiple sugar units and sodium carboxylate groups, representing the compound's detailed chemical formula.*

FDA Label Image

Figure 1 (Bridion 03)

A cumulative recovery rate graph showing the time to recovery in minutes on the x-axis and recovery rate on the y-axis. It compares sugammadex 2 mg/kg and neostigmine 0.05 mg/kg, both with rocuronium, illustrating faster recovery with sugammadex over a 120-minute period. Median recovery times are noted as 1.4 minutes for sugammadex and 21.5 minutes for neostigmine.*

FDA Label Image

Figure 2 (Bridion 04)

A Kaplan-Meier cumulative recovery rate graph comparing Recovery Time (in minutes) on the x-axis versus Cumulative Recovery Rate on the y-axis for BRIDION (sugammadex) 2 mg/kg and neostigmine 0.05 mg/kg when combined with vecuronium. The graph shows a faster recovery rate with sugammadex compared to neostigmine over a 120-minute period, with median recovery times indicated in an inset box.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.